Encouraging preliminary progress on their phase 2 schizophrenia drug has pushed the one year target to $40 currently at $5.65. Last breakout from this range in Jan 2021 resulted in a 350% surge in one week. There are few resistances ahead for consolidation at $8, 10, 14, 20.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.